121.22
price down icon0.98%   -1.20
after-market Dopo l'orario di chiusura: 121.22
loading
Precedente Chiudi:
$122.42
Aprire:
$122.29
Volume 24 ore:
7.05M
Relative Volume:
0.99
Capitalizzazione di mercato:
$150.40B
Reddito:
$29.05B
Utile/perdita netta:
$8.11B
Rapporto P/E:
18.78
EPS:
6.4563
Flusso di cassa netto:
$9.16B
1 W Prestazione:
-3.67%
1M Prestazione:
-1.11%
6M Prestazione:
+9.74%
1 anno Prestazione:
+29.80%
Intervallo 1D:
Value
$120.38
$122.53
Intervallo di 1 settimana:
Value
$120.38
$126.23
Portata 52W:
Value
$88.57
$128.70

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Nome
Gilead Sciences Inc
Name
Telefono
(650) 574-3000
Name
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Name
Dipendente
17,600
Name
Cinguettio
@GileadSciences
Name
Prossima data di guadagno
2025-02-11
Name
Ultimi documenti SEC
Name
GILD's Discussions on Twitter

Confronta GILD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
121.22 152.13B 29.05B 8.11B 9.16B 6.4563
Drug Manufacturers - General icon
LLY
Lilly Eli Co
1,010.31 907.99B 59.42B 18.41B 6.44B 20.22
Drug Manufacturers - General icon
JNJ
Johnson Johnson
201.93 487.83B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
226.08 404.22B 59.64B 2.36B 19.68B 1.3253
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
132.16 254.11B 54.45B 14.42B 17.15B 7.333
Drug Manufacturers - General icon
MRK
Merck Co Inc
99.72 250.41B 63.90B 19.05B 13.05B 7.5596

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-11-24 Ripresa Truist Buy
2025-11-13 Iniziato Scotiabank Sector Outperform
2025-08-19 Aggiornamento Daiwa Securities Neutral → Outperform
2025-08-08 Aggiornamento Truist Hold → Buy
2025-07-25 Aggiornamento Needham Hold → Buy
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-03-04 Reiterato Oppenheimer Outperform
2025-02-18 Aggiornamento Deutsche Bank Hold → Buy
2025-02-13 Aggiornamento DZ Bank Hold → Buy
2025-01-10 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2024-12-10 Ripresa BofA Securities Buy
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-14 Iniziato Citigroup Buy
2024-11-08 Downgrade Maxim Group Buy → Hold
2024-10-21 Aggiornamento Leerink Partners Market Perform → Outperform
2024-10-17 Iniziato Bernstein Outperform
2024-10-07 Aggiornamento Wells Fargo Equal Weight → Overweight
2024-07-08 Aggiornamento Raymond James Mkt Perform → Outperform
2024-05-01 Reiterato Maxim Group Buy
2024-04-24 Aggiornamento HSBC Securities Reduce → Hold
2024-02-22 Downgrade Truist Buy → Hold
2023-11-09 Iniziato Deutsche Bank Hold
2023-09-08 Aggiornamento BofA Securities Neutral → Buy
2023-09-06 Iniziato HSBC Securities Reduce
2023-07-24 Reiterato Barclays Equal Weight
2023-05-16 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-04-28 Ripresa Piper Sandler Overweight
2023-01-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-12-13 Ripresa BofA Securities Neutral
2022-12-09 Downgrade DZ Bank Buy → Hold
2022-10-31 Aggiornamento Barclays Underweight → Equal Weight
2022-10-28 Reiterato BMO Capital Markets Market Perform
2022-10-28 Reiterato Cowen Outperform
2022-10-28 Reiterato JP Morgan Overweight
2022-10-28 Reiterato Jefferies Buy
2022-10-28 Aggiornamento Piper Sandler Neutral → Overweight
2022-10-28 Reiterato RBC Capital Mkts Outperform
2022-10-28 Aggiornamento Truist Hold → Buy
2022-10-28 Reiterato Wells Fargo Equal Weight
2022-10-04 Aggiornamento JP Morgan Neutral → Overweight
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-05-23 Iniziato SVB Leerink Mkt Perform
2022-02-28 Downgrade BMO Capital Markets Outperform → Market Perform
2022-02-02 Reiterato BMO Capital Markets Outperform
2022-02-02 Reiterato BofA Securities Neutral
2022-02-02 Reiterato RBC Capital Mkts Outperform
2022-02-02 Reiterato Truist Hold
2022-02-02 Reiterato Wells Fargo Equal Weight
2022-01-28 Aggiornamento Argus Hold → Buy
2022-01-06 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-12-06 Iniziato Goldman Neutral
2021-11-19 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-11-19 Ripresa Piper Sandler Neutral
2021-10-20 Ripresa Cowen Outperform
2021-07-30 Reiterato BMO Capital Markets Market Perform
2021-07-30 Reiterato RBC Capital Mkts Outperform
2021-04-01 Aggiornamento Bernstein Mkt Perform → Outperform
2021-03-30 Aggiornamento Redburn Neutral → Buy
2021-01-19 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2021-01-04 Aggiornamento Guggenheim Neutral → Buy
2020-11-03 Ripresa Morgan Stanley Equal-Weight
2020-10-28 Iniziato UBS Neutral
2020-09-30 Ripresa Jefferies Buy
2020-09-15 Aggiornamento Maxim Group Hold → Buy
2020-07-31 Reiterato Credit Suisse Neutral
2020-07-31 Reiterato Morgan Stanley Equal-Weight
2020-07-31 Reiterato Piper Sandler Overweight
2020-07-31 Reiterato RBC Capital Mkts Outperform
2020-07-31 Reiterato SunTrust Hold
2020-07-31 Reiterato Wells Fargo Equal Weight
2020-07-20 Aggiornamento Credit Suisse Underperform → Neutral
2020-06-03 Aggiornamento SVB Leerink Mkt Perform → Outperform
2020-05-26 Aggiornamento SunTrust Sell → Hold
2020-05-01 Downgrade JP Morgan Overweight → Neutral
2020-05-01 Downgrade Raymond James Outperform → Mkt Perform
2020-05-01 Downgrade SunTrust Hold → Sell
2020-04-27 Downgrade UBS Buy → Neutral
2020-04-20 Downgrade BMO Capital Markets Outperform → Market Perform
2020-04-20 Downgrade Wells Fargo Overweight → Equal Weight
2020-04-17 Downgrade CFRA Hold → Sell
Mostra tutto

Gilead Sciences Inc Borsa (GILD) Ultime notizie

pulisher
07:54 AM

Marshall Wace LLP Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat

07:54 AM
pulisher
05:41 AM

CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035 by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players - GlobeNewswire Inc.

05:41 AM
pulisher
04:56 AM

Epoch Investment Partners Inc. Has $95.16 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat

04:56 AM
pulisher
04:18 AM

Gilead Sciences, Inc. $GILD Shares Bought by CW Advisors LLC - MarketBeat

04:18 AM
pulisher
02:58 AM

Sprint Bioscience (Q3 review)Gilead deal a strong confirmation - marketscreener.com

02:58 AM
pulisher
02:58 AM

Redeye: Sprint Bioscience (Q3 review)Gilead deal a strong confirmation - TradingView

02:58 AM
pulisher
01:18 AM

Is Gilead Sciences Inc. (GIS) stock good for long term investingJuly 2025 Rallies & Stock Timing and Entry Methods - Newser

01:18 AM
pulisher
Dec 04, 2025

Gilead's Seat at the Table of Conversations Centered Around HIV - Gilead Sciences

Dec 04, 2025
pulisher
Dec 04, 2025

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - Yahoo Finance

Dec 04, 2025
pulisher
Dec 04, 2025

VestGen Advisors LLC Lowers Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Dec 04, 2025
pulisher
Dec 04, 2025

Channing Capital Management LLC Purchases 43,875 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Dec 04, 2025
pulisher
Dec 04, 2025

Gilead Sciences, Inc. $GILD Shares Acquired by Guggenheim Capital LLC - MarketBeat

Dec 04, 2025
pulisher
Dec 03, 2025

Gilead (GILD) Valuation After Fresh Buy Rating and Extended Biktarvy Exclusivity Boost Investor Confidence - Yahoo Finance UK

Dec 03, 2025
pulisher
Dec 03, 2025

Gilead Sciences, Inc. $GILD Shares Bought by Loomis Sayles & Co. L P - MarketBeat

Dec 03, 2025
pulisher
Dec 03, 2025

Invesco Ltd. Buys 3,394,330 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Dec 03, 2025
pulisher
Dec 02, 2025

Jeffrey Bluestone Sells 5,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat

Dec 02, 2025
pulisher
Dec 02, 2025

Gilead Sciences (NASDAQ:GILD) CEO Sells $1,265,400.00 in Stock - MarketBeat

Dec 02, 2025
pulisher
Dec 02, 2025

Gilead Sciences (NASDAQ:GILD) Director Sells $356,515.50 in Stock - MarketBeat

Dec 02, 2025
pulisher
Dec 02, 2025

Gilead Sciences (NASDAQ:GILD) Director Sells $356,670.66 in Stock - MarketBeat

Dec 02, 2025
pulisher
Dec 02, 2025

Transcript : Gilead Sciences, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 11 - marketscreener.com

Dec 02, 2025
pulisher
Dec 02, 2025

Insider Activity Update: Jeffrey Bluestone Executes Options Exercise, Resulting In $296K At Gilead Sciences - Benzinga

Dec 02, 2025
pulisher
Dec 02, 2025

2,222 Shares in Gilead Sciences, Inc. $GILD Purchased by Valued Retirements Inc. - MarketBeat

Dec 02, 2025
pulisher
Dec 02, 2025

Panagora Asset Management Inc. Has $175.96 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Dec 02, 2025
pulisher
Dec 02, 2025

Shelton Capital Management Sells 3,380 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Dec 02, 2025
pulisher
Dec 02, 2025

Prossimo Advisors LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat

Dec 02, 2025
pulisher
Dec 01, 2025

Will Gilead Sciences Inc. (Common Stock) (GIS0) stock outperform value peersWeekly Trend Recap & Comprehensive Market Scan Insights - Newser

Dec 01, 2025
pulisher
Dec 01, 2025

Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus

Dec 01, 2025
pulisher
Dec 01, 2025

Gilead Sciences director Kramer sells $713,186 in stock By Investing.com - Investing.com India

Dec 01, 2025
pulisher
Dec 01, 2025

News Is Out hosting Gilead’s Choose U World AIDS Day panel - Dallas Voice

Dec 01, 2025
pulisher
Dec 01, 2025

Orleans Capital Management Corp LA Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat

Dec 01, 2025
pulisher
Dec 01, 2025

Railway Pension Investments Ltd Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Dec 01, 2025
pulisher
Dec 01, 2025

Grantham Mayo Van Otterloo & Co. LLC Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Dec 01, 2025
pulisher
Dec 01, 2025

Gifford Fong Associates Sells 25,000 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Dec 01, 2025
pulisher
Nov 30, 2025

Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz - The National Law Review

Nov 30, 2025
pulisher
Nov 30, 2025

Gilead (GILD) Earns Buy Rating at Truist as HIV Franchise Continues to Deliver - Finviz

Nov 30, 2025
pulisher
Nov 30, 2025

West Family Investments Inc. Has $1.35 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 30, 2025
pulisher
Nov 30, 2025

New York State Common Retirement Fund Sells 15,100 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Nov 30, 2025
pulisher
Nov 30, 2025

Schroder Investment Management Group Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 30, 2025
pulisher
Nov 30, 2025

Scotia Capital Inc. Sells 17,090 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Nov 30, 2025
pulisher
Nov 30, 2025

Level Four Advisory Services LLC Trims Stake in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 30, 2025
pulisher
Nov 30, 2025

Laurel Wealth Advisors LLC Acquires 6,593 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Nov 30, 2025
pulisher
Nov 30, 2025

Edgewood Management LLC Sells 2,394 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Nov 30, 2025
pulisher
Nov 30, 2025

Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Nov 30, 2025
pulisher
Nov 29, 2025

What Gilead Sciences (GILD)'s First Lenacapavir Shipments in Africa Mean For Shareholders - simplywall.st

Nov 29, 2025
pulisher
Nov 29, 2025

Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline - Insider Monkey

Nov 29, 2025
pulisher
Nov 29, 2025

Skandinaviska Enskilda Banken AB publ Acquires 252,108 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Nov 29, 2025
pulisher
Nov 29, 2025

WealthTrust Axiom LLC Decreases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 29, 2025
pulisher
Nov 29, 2025

State Board of Administration of Florida Retirement System Purchases 15,800 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Nov 29, 2025
pulisher
Nov 29, 2025

Quadrant Capital Group LLC Has $3.82 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 29, 2025
pulisher
Nov 28, 2025

Will Expanding Lenacapavir Access in Africa Reshape Gilead Sciences' (GILD) Global Healthcare Narrative? - Yahoo Finance

Nov 28, 2025
pulisher
Nov 28, 2025

Is Gilead Sciences a Bargain After 40% Share Price Surge and Pipeline Updates? - Yahoo Finance

Nov 28, 2025

Gilead Sciences Inc Azioni (GILD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Gilead Sciences Inc Azioni (GILD) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Bluestone Jeffrey
Director
Nov 28 '25
Sale
125.08
5,000
625,400
8,920
Kramer Kelly A.
Director
Nov 26 '25
Option Exercise
81.00
2,806
227,286
4,145
Kramer Kelly A.
Director
Nov 28 '25
Option Exercise
81.00
2,805
227,205
4,144
Kramer Kelly A.
Director
Nov 26 '25
Sale
127.11
2,806
356,671
1,339
Kramer Kelly A.
Director
Nov 28 '25
Sale
127.10
2,805
356,516
1,339
O'Day Daniel Patrick
Chairman & CEO
Nov 28 '25
Sale
126.54
10,000
1,265,444
571,203
drug_manufacturers_general PFE
$26.03
price up icon 1.28%
$329.89
price down icon 3.07%
drug_manufacturers_general SNY
$49.53
price up icon 1.21%
drug_manufacturers_general NVO
$47.86
price down icon 0.27%
drug_manufacturers_general MRK
$99.72
price down icon 1.16%
Capitalizzazione:     |  Volume (24 ore):